Cart
sales@molnova.com
Tesidolumab
CAS No. 1531594-08-7
Tesidolumab( —— )
Catalog No. M36737 CAS No. 1531594-08-7
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 471 | In Stock |
|
| 10MG | 787 | In Stock |
|
| 25MG | 1169 | In Stock |
|
| 50MG | 1535 | In Stock |
|
| 100MG | 2074 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTesidolumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody.
-
DescriptionTesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex.
-
In VitroTesidolumab (LFG316) possesses a half-life in humans of approximately 9 days.Tesidolumab (LFG316) binds to a distinct epitope to that of eculizumab and ravulizumab, distant to Arg 885.
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement System
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1531594-08-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jun-Ichi Nishimura, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022 Jun 1;107(6):1483-1488.?
molnova catalog
related products
-
ADH-503
ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.
-
NDT 9513727
NDT 9513727 is a potent, selective and orally bioavailable C5a receptor inverse agonist with IC50 of 11.6 nM in radioligand binding assay.
-
Sutimlimab
Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemolysis.
